IN BRIEF: Amryt Receives Reimbursement Approval For Myalepta

Amryt Pharma PLC - biopharmaceutical company - Says the National Institute for Health & Care ...

Alliance News 20 January, 2021 | 9:32PM
Email Form Facebook Twitter LinkedIn RSS

Amryt Pharma PLC - biopharmaceutical company - Says the National Institute for Health & Care Excellence has approved Myalepta for reimbursement in England and Wales as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy in adults and children two years of age and above and familial or acquired partial lipodystrophy in adults and children 12 years of age and above. Myalepta received marketing authorisation from the European Medicines Agency in 2018.

Current stock price: 206.00 pence, up 5.6% on Wednesday

Year-to-date change: up 6.2%

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Amryt Pharma PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures